Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 19;16(4):e58585.
doi: 10.7759/cureus.58585. eCollection 2024 Apr.

Side Effects and Adverse Events After Treatment With Teprotumumab for Thyroid Eye Disease: A Retrospective Observational Case Series

Fabliha A Mukit  1 , Andrew Manley  2 , Akash B Patel  3 , Marium Hashemi  2 , Jacquelyn F Laplant  4 , James C Fleming  5 , Brian T Fowler  5
Affiliations

Side Effects and Adverse Events After Treatment With Teprotumumab for Thyroid Eye Disease: A Retrospective Observational Case Series

Fabliha A Mukit et al. Cureus. .

Abstract

As the use of teprotumumab for thyroid eye disease (TED) becomes more prolific, there remains a scarcity of literature regarding the associated side effects and adverse events of teprotumumab use. The authors present a single-center retrospective, observational case review of TED patients who received at least a single dose of teprotumumab infusion at the oculofacial plastic surgery service between February 2020 and July 2023. The most predominant recollected side effects were fatigue, brittle nails, dry eye symptoms, hair loss, muscle spasms, and dry mouth. Significant adverse events were limited to two cases of a blood clot and a single case of pulmonary embolism. This is the first retrospective study of patient-reported side effects and adverse events experienced by a cohort of teprotumumab users.

Keywords: exophthalmos; igf-1 receptor antagonist; insulin-like growth factor 1 receptor (igf1-r); teprotumumab; thyroid eye disease.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

References

    1. Graves' ophthalmopathy. Bahn RS. N Engl J Med. 2010;362:726–738. - PMC - PubMed
    1. Thyroid eye disease: a review. Weiler DL. Clin Exp Optom. 2017;100:20–25. - PubMed
    1. Pathogenesis of thyroid eye disease: review and update on molecular mechanisms. Khong JJ, McNab AA, Ebeling PR, Craig JE, Selva D. Br J Ophthalmol. 2016;100:142–150. - PubMed
    1. New insights into the pathogenesis and nonsurgical management of Graves orbitopathy. Taylor PN, Zhang L, Lee RW, et al. Nat Rev Endocrinol. 2020;16:104–116. - PubMed
    1. The pathophysiology of thyroid eye disease. Shan SJ, Douglas RS. J Neuroophthalmol. 2014;34:177–185. - PubMed

LinkOut - more resources